Trial reportBlood advances2018
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).
Open access · goldAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 7 pooled it
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 7 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review and meta-analysis.Blood advances · 2026Pooled it
- Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes/neoplasms treated with decitabine: a systematic literature review.Annals of hematology · 2026Pooled it
- American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.Blood advances · 2026Guideline
- Comparative efficacy and safety in low-intensity treatment for acute myeloid leukemia in older patients: a systematic review and network meta-analysis.European journal of medical research · 2025Pooled it
- Efficacy of epigenetic agents for older patients with acute myeloid leukemia and myelodysplastic syndrome in randomized controlled trials: a systematic review and network meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.Journal of hematology & oncology · 2023Pooled it
- Pooled it
- A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.Cancer research communications · 2025Trial
- Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.Annals of hematology · 2025Trial
- Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101.Blood advances · 2022Trial
- Efficacy of 10-day decitabine in acute myeloid leukemia.Leukemia research · 2021Trial
- Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.Blood advances · 2020Trial
- Autophagy and Lipid Metabolism as a Therapeutic Target for Overcoming Drug Resistance in Acute Myeloid Leukemia.Life (Basel, Switzerland) · 2026Review
- DNA methyltransferase inhibitors in hematological malignancies and solid tumors.International journal of cancer · 2026Review
- Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia.Blood and lymphatic cancer : targets and therapy · 2026Review
- Article
- Article
- Expression and DNA methylation of 20S proteasome subunits as prognostic and resistance markers in cancer.Molecular oncology · 2025Article
- Deficit accumulation frailty index and treatment tolerability in AML: data from CALGB 11001 and 11002 (Alliance).Blood advances · 2025Article
- Inhibition of TOPORS ubiquitin ligase augments the efficacy of DNA hypomethylating agents through DNMT1 stabilization.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 13 institutions in 1 country.
Gail J RobozDivision of Hematology and Oncology, Department of Medicine, Weill Medical College, Cornell University, New York, NY.
Sumithra J MandrekarAlliance Statistics and Data Center, Mayo Clinic, Rochester, MN.
Pinkal DesaiDivision of Hematology and Oncology, Department of Medicine, Weill Medical College, Cornell University, New York, NY.
Kristina LaumannAlliance Statistics and Data Center, Mayo Clinic, Rochester, MN.
Alison R WalkerThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Eunice S WangRoswell Park Comprehensive Cancer Center, Buffalo, NY.
Jonathan E KolitzMonter Cancer Center, Northwell Health System, Lake Success, NY.
Bayard L PowellWake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC.
Eyal C AttarMassachusetts General Hospital, Boston, MA.
Wendy StockUniversity of Chicago Comprehensive Cancer Center, Chicago, IL.
Clara D BloomfieldThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Jessica KohlschmidtAlliance Statistics and Data Center, Mayo Clinic, Rochester, MN.
Krzysztof MrózekThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Duane C HassaneDivision of Hematology and Oncology, Department of Medicine, Weill Medical College, Cornell University, New York, NY.
Levi GarrawayDana-Farber/Partners CancerCare, Boston, MA.
Judit Jané-ValbuenaBroad Institute of Harvard and MIT, Cambridge, MA.
Michele BaltayBrigham and Women's Hospital, Boston, MA; and.
Adam TracyBroad Institute of Harvard and MIT, Cambridge, MA.
Guido MarcucciCity of Hope Comprehensive Cancer Center, Duarte, CA.
Richard M StoneDana-Farber/Partners CancerCare, Boston, MA.
Richard A LarsonUniversity of Chicago Comprehensive Cancer Center, Chicago, IL.
Broad Institute · USNewYork–Presbyterian Hospital · USThe Ohio State University · USMayo Clinic · USUniversity of Chicago · USAlliance Data (United States) · USAtrium Health Wake Forest Baptist · USBrigham and Women's Hospital · USCancerCare · USCity of Hope · USMassachusetts General Hospital · USNorthwell Health · USRoswell Park Comprehensive Cancer Center · US
Funding
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MTransgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3MSoutheast Clinical Oncology Research Consortium, Inc. (SCOR)UG1CA189858 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI Judith O Hopkins, William J Irvin · 2014 to 2026
$38.8MCancer Research Consortium of West Michigan (CRCWM)UG1CA189860 · NCI · COREWELL HEALTH · PI KATHLEEN YOST BUTLER · 2014 to 2026
$29.1MDelaware Christiana Care NCORPUG1CA189819 · NCI · CHRISTIANA CARE HEALTH SERVICES, INC. · PI GREGORY A MASTERS · 2014 to 2026
$21.6MNCORP of the Carolinas (Greenville Health System NCORP)UG1CA189972 · NCI · PRISMA HEALTH - UPSTATE · PI Ki Young Chung · 2014 to 2026
$17.9MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6MOSU as Network Lead Academic Participating Site for the NCI NCTNU10CA180850 · NCI · OHIO STATE UNIVERSITY · PI BLUM, KRISTIE A, CHAKRAVARTI, ARNAB · 2014 to 2018
$6.8MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareU10CA180867 · NCI · DANA-FARBER CANCER INST · PI BURSTEIN, HAROLD JOHN, KIBEL, ADAM S · 2014 to 2018
$6.2MPHARMACOLOGICAL MODULATION OF EPIGENETIC CHANTGES IN AMLR01CA102031 · NCI · OHIO STATE UNIVERSITY · PI GUZMAN, MONICA L, MARCUCCI, GUIDO · 2004 to 2017
$3.8MNCI National Clinical Trials Network-Network Lead Academic Participating SitesU10CA180836 · NCI · UNIVERSITY OF CHICAGO · PI CHMURA, STEVEN J, KINDLER, HEDY L · 2014 to 2018
$3.2MNCI NIH HHS P30 CA033572NCI NIH HHS R01 CA102031NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180836NCI NIH HHS U10 CA180838NCI NIH HHS U10 CA180850NCI NIH HHS U10 CA180854NCI NIH HHS U10 CA180866NCI NIH HHS U10 CA180867NCI NIH HHS U10 CA180882NCI NIH HHS UG1 CA189819NCI NIH HHS UG1 CA189858NCI NIH HHS UG1 CA189860NCI NIH HHS UG1 CA189972NCI NIH HHS UG1 CA233180
Abstract
Novel treatment strategies are needed for older patients with acute myeloid leukemia (AML). This randomized phase 2 trial compared the efficacy and safety of 20 mg/m
Indexed as
AgedAged, 80 and overAntineoplastic AgentsBortezomibDecitabineDisease-Free SurvivalDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansKaplan-Meier EstimateLeukemia, Myeloid, AcuteMaleMiddle AgedMutationRepressor ProteinsAntineoplastic AgentsASXL1 protein, humanBortezomibDecitabineRepressor ProteinsTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.